MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, and Kamau Therapeutics, a clinical-stage stem cell therapy gene correction company, today announced they are entering into a strategic platform license (SPL) agreement.
Federal government shutdown watch: FDA and industry prep for likely closure Oct. 1
The federal government is bracing for a shutdown if lawmakers on Capitol Hill can’t rally enough votes to keep the government funded by the end
September 29, 2023